Hanning Tang
Key Laboratory Of Hematology
Nanjing, China
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial).
Journal: Journal of the National Cancer Center
Published: September 08, 2025
Efficacy and safety of orelabrutinib combined with rituximab and high dose methotrexate in primary or secondary central nervous system diffuse large B-cell lymphoma: a retrospective analysis.
Journal: Investigational new drugs
Published: March 10, 2025
Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non-germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG).
Journal: BMC medicine
Published: February 15, 2025
Exploring the Role of EBV Infection in EBV-T/NKLPD With EBV Capture Technology Based on Single-Cell RNA Sequencing.
Journal: Journal of medical virology
Published: July 29, 2024
Multiple primary malignancies in 788 Chinese patients with diffuse large B-cell lymphoma.
Journal: Cancer medicine
Published: November 11, 2022
Overexpression of c-Myc-dependent heterogeneous nuclear ribonucleoprotein A1 promotes proliferation and inhibits apoptosis in NOTCH1-mutated chronic lymphocytic leukemia cells.
Journal: Chinese medical journal
Published: June 22, 2022
Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib-resistant chronic lymphocytic leukaemia.
Journal: Molecular oncology
Published: December 06, 2021
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies.
Journal: Journal of hematology & oncology
Published: December 10, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026